`
`From:
`Sent:
`To:
`
`Cc:
`
`Subject:
`
`Anstaett, David L. (Perkins Coie)
`Friday, April 01, 2016 2:17 PM
`Bennett, John T; Prew, Brian J (BPrew@goodwinprocter.com); Wiesen, Daryl L;
`'BRobinson@goodwinprocter.com' (BRobinson@goodwinprocter.com)
`Bloodworth, Shannon (Perkins Coie); White, Brandon (Perkins Coie); Greb, Emily J.
`(Perkins Coie)
`Copaxone 40 discovery
`
`John,
`
` I
`
` write to follow up on Wednesday’s meet-and-confer call. We accept Plaintiffs’ proposal to remove
`all confidentiality designations from those portions of Dr. Wolinsky’s deposition transcript
`specifically identified in my February 26, 2016 letter to you. As of now, we will treat those portions of
`the Wolinsky deposition transcript as public. In exchange, we agree to withdraw our request in my
`February 26 letter to de-designate the identified portions of Dr. Pinchasi’s transcript.
`
`
`
`
`
`Best,
`Dave
`
`
`(cid:120)
`
` (cid:3)
`
` (cid:3)
`
`(cid:3)
`
`
`
`(cid:3)
`
`(cid:3)
`
`(cid:3)
`
`1
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`MYLAN PHARMS. INC. EXHIBIT 1145 PAGE 1
`
`
`
`
`
`
`
`
`
`
`
`(cid:3)
`
`
`
`
`
`
`
`(cid:120)
`
`(cid:3)
`
`
`
`David Anstaett | Perkins Coie LLP
`PARTNER
`One East Main Street Suite 201
`Madison, WI 53703-5118
`D. +1.608.663.5408
`F. +1.608.663.7499
`E. DAnstaett@perkinscoie.com
`
`(cid:3)
`
`2
`
`MYLAN PHARMS. INC. EXHIBIT 1145 PAGE 2